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Healthcare costs can be astronomical when it comes to cancer treatment. Given the 
steep costs of treatment, it is expected for a patient to learn about the cost estimates before 
starting the treatment process. Having this information would be immensely helpful for the 
patient to avoid debt and the debt related stress at the end of the treatment cycle. This would 
also help MD Anderson Cancer Center to improve patient experience and payer 
performance. Therefore, it is crucial for the Cancer Center to have a robust analytical tool 
to predict the stages and costs of treatment for a given set of conditions and patient 
attributes. By analyzing the various factors driving the costs and the attributes affecting the 
condition of the patient, the treatment costs can be predicted more accurately than the state 
of the art. This paper analyzes the various factors affecting the costs by measuring the 
variance of expenses at different stages of treatment. Further, the condition of the patient 
was modelled as a stochastic process to have an in-depth knowledge of the likelihood of 
the patient’s condition getting better or worse given the stage at which the patient entered 
the system. 
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The University of Texas MD Anderson Cancer Center is one of the world’s largest 
centers dedicated to the cause of cancer patient care, research education and prevention. [4] 
The Revenue Cycle Management team at the Cancer Center is primarily involved with 
performing cost analysis, measuring profitability and analyzing payer performance. The 
concern that they had with their analysis were the inaccuracies in predicting the cost for a 
new patient. The inaccuracies do not pose a major issue for insured patients, as their 
insurance will take care of the majority of the costs, but we have to keep in mind that 
copays can be very expensive too. However, the patients without any insurance have to 
face unexpected expenses which are not accounted for in their initial cost estimate.  
United States has the most expensive healthcare system in the world. [3] The country 
doesn’t have a nationwide system of health insurance, however insurance can be bought 
from a private marketplace or provided by the government. [2] Cancer treatment however, 
is very expensive and drags on for a very long period of time. Given that 75.1% of a 
staggering $5 billion worth of revenue earned by MD Anderson Cancer Center came from 
the patients [4] (both insured and self-pay), it is of importance for us to make the patient 
experience better by providing accurate estimations for their treatment and help them 
prepare better financially. 
For our analysis we were provided with data sets for Melanoma, Breast Cancer and 
Gynecological Cancer. In the next sections, the paper discusses how factorial analyses were 
performed on certain categorical variables to identify features affecting the costs. This 
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analysis takes cues from the work done by Bertsimas Et al [1]. Further it discusses the 
process of obtaining the probability of the condition of a patient getting better or worse at 
different stages of treatment. Python packages like pandas and seaborn have been used 
extensively in this project for analyzing and visualizing the data respectively. The analysis 
sheds some light on the major factors driving up the costs and provides valuable insights 
on the treatment cycle of cancer patients. 
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Objectives 
In order to understand the core factors driving the costs the initial objectives were 
to perform exploratory analysis into the dataset. The key objectives were to: 
1. Find cost estimates for new patients over their period of stay, especially for Self-
Pay1 patients. These estimates were measured by expenses per month and 
cumulative expenses over the period of treatment. 
2. Identify the important factors that affect the costs by analyzing the variance of costs 
split by the factor levels. For example, the costs were split by gender to see if there 
was a significant difference between the treatment costs for males and females. 
3. Investigate the metastasis of cancer by observing the stochastic nature of the acuity 
levels of the patient over the period of treatment. 
 
                                                 
1 Patients without an insurance cover for their treatment. 
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Revenue Cycle 
Before diving into understanding the dataset and the analysis, it is of importance 
for us to understand how the Revenue Cycle works. Here “cycle” means the entire process 
of treatment starting from admission or pre-admission process till the final bill settlement. 
This process goes through various stages of treatment, accounting and settlement.  
Once a patient is admitted for a particular treatment, a Patient Medical Record 
Number (Patient MRN) and a Hospital Account Record (HAR) is created for the patient. 
This account keeps track of all the expenses falling under that treatment cycle. A patient 
can have multiple HAR records based on the different treatments received. Each procedure 
performed on the patient is called an encounter and each encounter is a subset of a particular 
HAR. These encounters are identified by a Contact Serial Number (CSN). A bunch of 
CSNs come under the umbrella of a unique HAR; similarly, a bunch of HARs constitute a 
Patient MRN. The tree diagram of the hierarchy of the codes is given in figure 1. 
 
Figure 1: Schematic representation of cost clustering hierarchy. 
 
The entire cycle is represented by figure 2. The diagram shows the revenue cycle 
starting from the patient’s admission/pre-admission process till the point when the account 
is fully cleared and given a “$0 Account Balance” status. 
Patient MRN 
HAR-1 HAR-2 HAR-3 
CSN-4 CSN-5 CSN-1 CSN-2 CSN-3 
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Figure 2: Schematic representation of revenue cycle. 2 
 
 
                                                 
2 Image Courtesy: The UT MD Anderson Cancer Center 
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Dataset 
For our analysis, we obtained the datasets for patients diagnosed and treated for 
melanoma, breast cancer, and gynecologic cancer. The datasets consisted of costs incurred 
by the patients per procedure per day, along with additional details for identifying features 
impacting the costs starting from March of 2016 to March of 2018. Each dataset consisted 
of two sheets of information. One was the Hospital Billing (HB) sheet which was the 
records of costs for the material/facility use during the treatment. Here “material” means 
the treatments like chemotherapy, blood transfusions, injections etc. The second sheet was 
the Provider Billing (PB) sheet. This sheet provided the cost breakdowns for the service 
charges by various providers involved in the treatment process, e.g. nurses, surgeons etc. 
The datasets obtained were in .xlsx format and were imported to python using 
pandas. Pandas is a powerful tool in Python which helps in easier cleansing of datasets and 
has optimized functions to slice and dice the data. Pandas’ built in functions were used to 
convert the dataset into a dataframe3 for easier usability in the code.  
After parsing the data, it was observed that there were 32 columns in the HB dataset 
and some of those did not have any direct relation with the cost of the patient, but those 
factors were important for clustering the various branches of expenses. The cost clustering 
has not been performed in our analysis. Various branches of expenses refer to the tree 
diagram as given in figure 1. The different columns of importance were the “Patient MRN”, 
“Gender”, “Age”, “Primary Payer”, “Service Date”, “Registration Date”, “Procedure 
                                                 
3 A data structure representing cases (rows), each of which consists of a number of observations or 
measurements (columns). 
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codes”, “CPT/HCPCS codes”, “Revenue Codes” and “Total charge”. These fields have 
been described in detail below. 
AGE 
The age attribute makes intuitive sense as a factor for analysis, since the age 
vulnerability, required treatments and recovery rates will be different for patients in 
different age groups. For our initial analysis we checked the number of patients in each age 
group. It was observed that the patients in the age group between 55 and 65 were the most 
vulnerable to Melanoma and Gynecologic cancers. While the vulnerable age for breast 
cancer was observed to be between 40 and 60. Further, given that breast cancer is more 
predominant in females and gynecologic cancer affects females only, it is worthwhile to 
note that women have a marginally higher risk of developing gynecologic cancer in their 
60s than that of breast cancer, going by the observations. 
 
 




Figure 4: Number of patients by age for Breast Cancer dataset 
 
 
Figure 5: Number of patients by age for Gynecologic Cancer dataset 
 
GENDER 
Similar to age, gender was also taken into consideration to observe the 
differentiation in the treatment cost. But the effect of gender was not considered for the 
breast cancer and gynecologic cancer datasets. For example, in the gynecologic cancer 
dataset, out of the 3167 patients in the dataset, only 5 patients were Male. Similarly, we 
observed that only 45 out of 4562 patients in the Breast cancer dataset were males. Plotting 
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the total cost of treatment with gender as a factor would show a very high variability for 
males for the above-mentioned datasets. Therefore, including gender as a factor would not 




The primary payer field identifies the source of payment for the cancer treatment. 
The patients paying out of pocket have been marked as “Self-Pay”. If the insurance 
company is paying for the treatment, then the name of the particular insurance provider is 
mentioned in this column. We identified that a very small portion of the patients were Self-
Pay. But that was the basic objective of our analysis. After looking more thoroughly into 
the data, it was observed that there was no difference between the procedure costs for the 
Self-Pay patients compared to the insured patients, and all patients were treated equally. 
This provided enough evidence to drop the payer type differentiation, as the goal of cost 
estimation can still be achieved without it. 
SERVICE DATE 
This variable records the date on which the patient received a particular service. 
This field was used to measure the stages of the expenses incurred over the length of 
treatment. This field also came in handy for the Breast Cancer and Gynecologic Cancer 




The registration date field represents the date on which a patient was registered on 
the MD Anderson system to receive treatment. This field gives us the starting point of 
treatment and helps us measure the relative time spent in treatment. 
The calendar month and year of services are not related to cost of treatment. Rather, 
we want to know how many months have passed since the time a patient was admitted for 
treatment. The time of treatment here implies the time elapsed from the start of treatment 
till the current service date inn consideration. This way, we can analyze the data for all 
patients based on their time of registration irrespective of the date of admission. 
Thus, 
Time of treatment = Service Date – Registration Date  
The Registration Date field was available for the Melanoma dataset. However, the 
same information was not available for the Breast Cancer and Gynecologic Cancer dataset. 
For those cases, we assumed that the earliest service date for a patient in the dataset as 
Registration Date. 
For Gynecologic and Breast Cancer datasets, 
Time of treatment = Service Date – Minimum of Service Date 
 
CPT/HCPCS CODE 
Current Procedural Terminology (CPT) or the Healthcare Common Procedure 
Coding System (HCPCS) codes are useful in identifying specific procedure types. For our 
 11 
study, we noticed that chemotherapy is one of the major methods in cancer treatment. So 
the average amounts were estimated separately for chemo and non-chemo treatments. 
The procedure codes starting with the letter “J” were identified as chemotherapy 
related. The patients with at least one CPT/HCPCS code starting with the letter J were 
marked as chemo and other patients were marked as non-chemo. 
REVENUE CODE 
The revenue code section provides us valuable information about the various 
procedure groups that drive up the costs.  Analyzing the effect of procedures directly as a 
factor is not very effective in our analysis, since there are hundreds of different procedures 
involved in the treatment for the different patients. That is where the revenue code 
groupings data is useful to perform analysis over fewer factors. 
 
TOTAL CHARGE 
Each procedure performed on a patient on a single date has a cost associated with 
it. The procedure might be repeated multiple times on the same day of treatment. The Total 
Charge column accounts for the charge incurred for each procedure multiplied by the 
number of repetitions. The cost per procedure can be derived by dividing the total charge 
by the “qty” (Quantity4) column. Per procedure cost is not an important factor in our 
analysis so we won’t be going into the details of this variable. 
                                                 
4 The quantity column represents the repetition of a procedure on the same day of treatment. 
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Preprocessing 
Before stepping into the factorial analysis, it was important for us to standardize 
the length of treatment for all the patients by setting the start of treatment to a base of zero 
(as discussed in the Service Date/Registration Date sections previously). A new column 
was added to the imported dataset to represent the number of months of treatment elapsed 
since the start of treatment. This column was named “nb_months”. The snippet in figure 6 
demonstrates the same. 
 
Figure 6: New column to account for the time elapsed in treatment in months 
 
After adding the treatment time column, it was easy to combine the costs per month 
per patient. Other attributes like age, gender etc. were also preserved to be used later for 
factorial analysis. Next, to differentiate the patients on the basis of chemotherapy 
treatments the code (Appendix 1) iterated through the entire dataframe and identified the 
Patient MRNs with at least one CPT/HCPCS code starting with J and stored it in a separate 
list named “chemoMRN”. A new column was created to identify the chemo/non-chemo 
patients. The default value was set to “non-chemo”. The code (Appendix 1) iterated 
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through the dataframe again to check which Patient MRNs were available in the 
“chemoMRN” list and changed the value to “chemo” in the “chemo/non-chemo” column. 
A sample data snippet is provided in figure 7, where we observe the total charge amount 
per month by length of treatment for a patient who underwent chemotherapy. 
 
Figure 7: A snippet demonstrating a patient data for chemotherapy.5 
 
                                                 




The analysis of the costs starts off with the melanoma dataset. Since this dataset 
has the gender differentiation, it would be of value to check that analysis first. Then we 
will be moving on to the Breast Cancer and Gynecologic cancer analyses.  
MELANOMA DATASET 
To have a clear idea about the variabilities and averages we are going to observe 
ahead, some initial probing is needed. The average cost of treatment over the time-elapsed 
with some information on the number of patients in the system gives us a good initial 
measure of costs and variability factors. Figure 8 helps us visualize the same. As we can 
observe from the graph, the costs shoot up steeply for the initial 6 months of treatment, 
after which the costs settle down relatively towards the later stages of treatment. Further, 
the number of patients decline rapidly after the 4th month of treatment. Therefore, the 
variability in the costs will visibly increase as the number of observations thin out towards 






Figure 8: Average monthly charges for Melanoma patients over the period of 
treatment with number of patients marked in red. 
 
 
Gender as a differentiating factor 
Next the analysis for the dataset is shifted towards the differentiation levels, by 
observing the spread of the expenses per month for patient gender as the differentiating 
factor as shown in figure 8. The graphs show the total charges per month over the duration 
of treatment for HB and PB charges. The Provider (PB) charges are not very different for 
male and female patients over the period of treatment. However, it is clearly observed that 
the charges for male and female patients are very different from each other for the HB 
charges. As per table 1, the ratio of average charges for male vs female melanoma patients 
is roughly 1.45.  
When we take a look at the cumulative charges for the patients over the period of 
treatment, we observe that the treatment costs are similar for male and female patients for 
the early stage of the treatment, however the costs start to diverge significantly after the 9th 
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month of treatment. Further, we notice that the costs seem to have a high variance towards 
the later stages of treatment. This variability is visibly higher due to fewer number of 
observations in that time frame and 90% confidence interval limit. The vertical bars 
represent the confidence interval for each of these graphs. 
 
Figure 9: Average monthly charges for Melanoma patients over the period of 
treatment factored by gender 
 
Gender Count of Patients 
Average Charges 
per month (in USD) 
Female 1272 59958 
Male 1565 87126 
Table 1: Average charges in USD by gender for Melanoma patients approximated to 




Figure 10: Cumulative charges for Melanoma patients over the period of treatment 
factored by gender 
Age as a differentiating factor 
Just like the differentiated the costs on the basis of gender, the expenses can be 
differentiated on the basis of age. For this representation the ages were grouped by a range 
of 20 years and a graph of the cumulative expenses was plotted for the HB and PB charges, 
as given by figure 11 below. Here we observe that the melanoma patients in the age range 
of 40-60 years are charged the highest for treatments. This might be an indication that the 
acuity levels for this age group might be higher compared to other age groups. 
Further, the patients in the 0-20 years age group finish their treatment the earliest. 
The cost of patients in the 20-40 years age group has the highest variance.  
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Figure 11: Cumulative charges for Melanoma patients over the period of treatment 
factored by age 
Chemotherapy as a differentiating factor 
Out of all the analyses we have performed, this differentiation gives us the most 
significant divergence in patient costs. For this analysis we have marked out the patients 
who underwent chemo therapy and who didn’t. Figure 12 illustrates the difference in costs. 
As we observe here, the cost for patients undergoing chemotherapy is not even comparable 
to the costs of patients who do not. This provides us with useful insight towards cost 
estimation for non-chemo type patients. We can predict the costs for non-chemo patients 
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with a very high degree of accuracy. In this graph we see an anomaly in the starting values 
for the time in treatment. The negative values signify that the patient(s) got registered for 
treatment after a few preliminary tests at MD Anderson’s facilities. Hence, although their 




Figure 12: Cumulative charges for Melanoma patients over the period of treatment 
factored by chemo/non-chemo treatments 
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BREAST CANCER AND GYNECOLOGIC CANCER DATASETS 
The analyses performed for both of these data sets are similar since gender is not a 
significant factor for either. Hence, we will only look into the effects of age and 
chemotherapy on the cumulative cost of treatment. 
Age as a differentiating factor 
By following a similar approach as the previous dataset, figures 13 and 14 illustrate 
the effect of age on breast cancer and gynecologic cancer treatment costs respectively. The 
graphs for HB and PB charges for breast cancer show a lot of similarity.  
The average cost for patients is highest in the 20-40 years range, followed by 40-
60, 60-80 and 80-100. This ordering applies to both the charges. Further, it sheds some 
light on the 0-20 range age group. As we can see, there aren’t many instances of patients 
in that age group. Further a long-term treatment was not necessary in that case and the costs 
were very manageable. 
Coming to the Gynecologic cancer data (figure 14), we observe that the average 
cost of treatment for women in the range of 20-40 years is relatively lower than other age 
ranges. Further the instances of this type of cancer showing up in the below 20 years age 





Figure 13: Cumulative charges for Breast Cancer patients over the period of treatment 
factored by age 
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Figure 14: Cumulative charges for Gynecologic Cancer patients over the period of 
treatment factored by age 
 
Chemotherapy as a differentiating factor 
Figures 15 and 16 illustrate the effect of chemotherapy on the cumulative costs. For 
both the breast cancer and gynecologic cancer datasets, we observe similar patterns as we 
did for the melanoma dataset. The patients undergoing chemotherapy end up paying way 
higher in comparison to the non-chemo patients. Also, the cost for non-chemo patients can 
be estimated fairly accurately even for a long period of treatment. 
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Figure 15: Cumulative charges for Breast Cancer patients over the period of treatment 




Figure 16: Cumulative charges for Gynecologic Cancer patients over the period of 




Acuity Level Transition Rates 
The information about the transition rates from one acuity level to another can play 
a significant role in predicting the cost of the treatment. The acuity level defines the severity 
of the patient condition and the level of treatment required to resolve the same. Level 1 is 
defined as a low acuity and level 5 as high acuity. The digits from 1 to 5 are derived from 
the unit’s place number from the table in appendix 2. For the calculation to make some 
sense, we defined a value “0” which represents a state when a patient has not yet entered 
the system or the state which has not been recorded after the last service date for a particular 
patient. 
The concept of a Discrete Time Markov Chain has been used here to create a 
transition matrix. The following steps were followed to obtain the matrices: 
1. The “Patient MRN”, “Service date” and “CPT/HCPCS code” columns were 
extracted from the dataset to create a new dataframe. 
2. This new dataframe was sorted by service date to create a chronological order of 
records.      
3. The code iterated over the dataframe to check if the CPT code matched with the 
ones provided in appendix 2. If it did then the last digit of the CPT code was 
extracted and appended to the list of last digits for a specific Patient MRN. 
4. A dictionary of lists was created with Patient MRNs as keys and list of last digits 
as the value. 
5. Next, as per the algorithm, the digit zero “0” was prefixed to each list to identify 
“outside of the MD Anderson system” status. Then all the lists were concatenated. 
6. The algorithm then created another dictionary by storing the values of the acuity 
levels as keys along with the zero, and the list of probabilities of transitioning to 
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another digit as the values. For example, the key 1 might have the following 
probability values (dummy values used as a representation): 
 1: [0: 3.6%, 1: 0%, 2: 56%, 3: 22%, 4: 10%, 5: 8.4%] 
 
In the above representation we can observe that the transition from acuity level 1 
to 1 is zero, this is because we are not considering same state transitions as the information 
on the order of placement of acuity level in the CPT codes is unclear. Further, we notice 
that the probabilities sum up to 100%, which means that the patient will definitely transition 
to another state. To read the transition table, consider the digits from 0 to 5 written 
vertically as the acuity level at any given point of time and the horizontal digits 0 to 5 as 
the possible future acuity levels. “0” in the current time step represents the status of the 
person as “Outside of MD Anderson system”, whereas the “0” in the future step represents 
an unknown state, since the dataset is not yet exhaustive about the full treatment cycle. 
Tables 2, 3 and 4 show the transition rate probabilities for Melanoma, Breast Cancer 
and Gynecologic Cancer. The color schemes are picked to match the ribbon colors 
representing each cancer type.6 Further the patchy nature of the colors provide a heat map 
of values. Higher probabilities have darker tones whereas lower probabilities fade towards 
white. 
These probability values can provide crucial insights towards the effect of treatment 
and cost predictions. A cost estimate can be associated to an acuity level and the probability 
of transition between the different acuity levels can provide us with the basis to find a 
weighted average of the total cost. 
                                                 
6 Black (used grey) for Melanoma, Pink for Breast Cancer and Teal for Gynecologic Cancer 
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Although it is theoretically possible to gauge the cost from these probability 
matrices, it’s unclear how the acuity level might change in the future for the patients in the 
dataset. A longer-term dataset will be more valuable for such an analysis. 
 
  Acuity level at the next time step 
  0 1 2 3 4 5 
Acuity Level 
at the current 
time step 
0 0.00% 1.40% 2.20% 55.00% 37.50% 3.90% 
1 5.40% 0.00% 3.10% 47.40% 39.70% 4.40% 
2 0.80% 5.80% 0.00% 69.90% 22.40% 1.10% 
3 7.50% 9.00% 9.80% 0.00% 68.20% 5.60% 
4 55.30% 2.20% 1.60% 39.10% 0.00% 1.90% 
5 43.00% 1.80% 1.60% 33.40% 20.10% 0.00% 
Table 2: Acuity level transition rates for Melanoma patients.  
  Acuity level at the next time step 
  0 1 2 3 4 5 
Acuity Level 
at the current 
time step 
0 0.00% 3.10% 3.80% 50.30% 26.50% 16.20% 
1 1.10% 0.00% 3.00% 49.70% 31.70% 14.60% 
2 1.30% 3.90% 0.00% 60.10% 26.00% 8.80% 
3 3.30% 9.00% 8.10% 0.00% 60.10% 19.60% 
4 9.50% 5.70% 4.10% 66.10% 0.00% 14.50% 
5 52.30% 2.70% 1.70% 26.30% 17.00% 0.00% 
Table 3: Acuity level transition rates for Breast Cancer patients.  
  Acuity level at the next time step 
  0 1 2 3 4 5 
Acuity Level 
at the current 
time step 
0 0.00% 1.40% 1.30% 44.30% 43.30% 9.70% 
1 1.60% 0.00% 3.00% 43.40% 42.70% 9.40% 
2 2.30% 5.50% 0.00% 49.90% 35.20% 7.10% 
3 7.00% 8.80% 5.20% 0.00% 61.10% 17.90% 
4 38.40% 4.60% 2.10% 45.60% 0.00% 9.30% 
5 46.40% 3.60% 1.40% 28.40% 20.10% 0.00% 
Table 4: Acuity level transition rates for Gynecologic Cancer patients. 
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Results 
The analysis provided us with some valuable insights regarding the various factors 
affecting the cost of treatment for the various kinds of cancer. We observed that each of 
the analyzed factors, i.e. age, gender and chemotherapy play a major role in differentiating 
the costs. Chemotherapy status showed the highest effect on the cost. Whereas age 
differentiation showed subtle but important differences in costs for each age range.  
Coming to the transition rate probabilities, we observed that melanoma patients 
(figure 3) have the highest probability of entering the system at acuity level 3. Further, the 
probability of the condition worsening from level 2 to 3 and 3 to 4 are the highest in the 
matrix. Similar patterns were observed for Breast Cancer and Gynecologic Cancer acuity 
levels. But, due to the limitation on the length of the observations, it was hard to gauge the 
transition from the higher acuity levels back to lower ones. This is portrayed by the high 
transition rates from level 4 and 5 to level 0. Datasets over longer time periods might be 
more useful in these cases. 
Based on these observations, we can approach towards building more 
comprehensive models to predict costs. The data collected from the patient before 
registering him/her on the system is crucial for us to predict the possible outcomes and the 
associated cost during the treatment. Having this information would help us build a more 
robust training set. Further, the categorical variables present in the dataset, e.g. diagnosis 
codes, procedure codes etc., need to be limited to fewer factor levels to fruitfully analyze 
their effects on the cost.  
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Appendix 1: Pseudo Codes 
Pseudo Code for chemo/NonChemo: 
START 
SET ChemoMRN to 0  
FOR each PatientMRN find RegDate = min(ServiceDate) 
Time-of-Treatment = ServiceDate – RegDate 
IF CPTcode starts with J THEN  
     Append ChemoMRN  
ELSE  
     BREAK 
END IF  
GROUPBY PatientMRN, Gender and Time-of-Treatment for ChemoMRN 
PLOT data by Cumulative cost and Average monthly cost 
END 
Pseudo Code for Acuity levels: 
START 
SET acuityMRN to 0  
FOR each PatientMRN find RegDate = min(ServiceDate) 
Time-of-Treatment = ServiceDate – RegDate 
CONVERT PatientMRN to Object 
IF CPTcode ends with acuity-level THEN  
     Append acuityMRN  
ELSE  
     BREAK 
END IF  
GROUPBY PatientMRN, Gender and Time-of-Treatment for acuityMRN 




Appendix 2: Acuity Level codes 
 
CPT Category CPT HCPCS Code 




 99215  High Acuity 
  




 99205  High Acuity 
  




 99245  High Acuity 
  
Table 5:  Acuity levels by CPT codes 
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